Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | NT5E | P21589 | 2/20 | 0.40 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.39 |
| ▸ | AHCY | P23526 | 1/20 | 0.36 |
| ▸ | PNP | P00491 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5694100 | 0.93 | NT5E (0.48) | NT5EP2RY1PNPLMNATP53 | |
| SCHEMBL5908147 | 0.90 | CA5A (0.40) | CA5ANT5EP2RY1 | |
| SCHEMBL5694106 | 0.90 | POLB (0.45) | P2RY1PDE4DPDE3ASMN1; SMN2 | |
| SCHEMBL5694389 | 0.85 | DNMT1 (0.40) | NT5EP2RY1LMNATP53HTT | |
| SCHEMBL5908160 | 0.85 | POLG (0.39) | P2RY1 | |
| SCHEMBL5908150 | 0.84 | NT5E (0.45) | NT5EP2RY1PNPLMNATP53 | |
| SCHEMBL5694113 | 0.81 | POLB (0.42) | LMNAPDE3A | |
| SCHEMBL5908146 | 0.80 | P2RX3 (0.45) | P2RY1 | |
| SCHEMBL5694161 | 0.78 | LMNA (0.40) | NT5ELMNASMN1; SMN2 | |
| SCHEMBL5694235 | 0.77 | NT5E (0.46) | NT5EP2RY1PDE4DPDE3ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060167241-A1 | Method for synthesizing cyclic bisdinucleoside | MITSUI CHEMICALS, INC. (JP) | 2006-07-27 | — | — | US | disclosed |
| EP-1645561-A1 | METHOD OF SYNTHESIZING CYCLIC BISDINUCLEOSIDE | Mitsui Chemicals, Inc. (JP) | 2006-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167241-A1 | Method for synthesizing cyclic bisdinucleoside | NSUN2, POLR2H, POLB | CA5A 2831/4885NT5E 1192/4885P2RY1 3789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.